Dr. Wang’s Commitment to COTA’s Mission and Extensive Oncology Background Supports The Company’s Next Stage of Growth and Ongoing Partnerships 

Boston, Mass. – March 5, 2020 – COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, today announced its board of directors has appointed C.K. Wang, M.D. as the company’s chief medical officer (CMO). Since joining COTA in 2018, Dr. Wang has demonstrated his dedication to advancing COTA’s mission of improving cancer care and treatment through his leadership of clinical data abstraction operations. In his new role, Dr. Wang will be leading the medical team to meet the interest and demand for real-world data in cancer care. 

“Since joining COTA, I’ve been able to collaborate with provider and life science partners as we move closer to our shared vision – that everyone touched by cancer receives a clear path to care,” said Dr. Wang. “We’re on the cusp of truly changing how real-world data is applied in cancer care and drug discovery, and I look forward to continuing to drive this industry transformation in my expanded role.” 
“As COTA enters its next phase of growth, we are proud that our executive leadership team is fully aligned and embodies a steadfast commitment to our mission of bringing clarity to cancer care,” said Mike Doyle, President and CEO of COTA. “Dr. Wang’s impact on our organization to date has been truly remarkable. His perspective, developed from over a decade managing cancer practices and establishing new cancer programs, will be a great asset to COTA as we develop new oncology solutions to serve our partners across the industry. We look forward to applying his unique skill set across a broader set of initiatives as we continue to improve cancer care for patients.”

Prior to working with COTA, Dr. Wang served as the Acting Deputy Chief Health Officer for Oncology/Genomics and the Global Oncology Leader at IBM Watson Health.  Earlier in his career as a medical oncologist, Dr. Wang worked in private practice in the Dallas/Fort Worth area where he held multiple management and leadership positions including managing partner with Dallas Oncology Consultants, P.A., Director of Oncology with Medical Clinics of North Texas, P.A. and Cancer Program Chairman with the USMD Hospital in Arlington. He received his undergraduate training at Washington University in St. Louis and his M.D. from the University of Texas Health Science Center at San Antonio before completing his residency at University Hospitals in Cleveland, OH and his hematology/ oncology fellowship at the University of Texas Southwestern Medical Center.

About COTA, Inc.

Founded by doctors, engineers and data scientists, COTA is committed to bringing a patient first approach to cancer care through the use of real-world evidence. The Company organizes fragmented, often hidden data from the real world to provide clarity in cancer care. Combining clinical expertise in cancer with proprietary technology and advanced analytics, COTA helps inform decisions and action in oncology. COTA partners with providers, payers, and life science companies to ensure that everyone touched by cancer has a clear path to the right care. To learn more about COTA and how to make better decisions with the right data, visit cotahealthcare.com